Episode 33: Diana Sims-Silbermann, Clinician and Former Senior Trial Manager at Janssen Pharmaceuticals

Few & Far Between: How Biotech Gets Built

Sep 20 2023 | 00:26:33

00:00 / 00:26:33

Show Notes

Episode Transcript

"Having come from the clinical trial side, I then went to the management side. So, I understood all the problems that occur or arise when a clinical trial is being conducted - knowing what to watch out for, why the protocol is written the way it is. So that was an immense help." - Dr. Diana Sims-Silbermann Biorasi CEO, Chris O'Brien, welcomes Dr. Diana Sims-Silbermann to the latest episode of the Few & Far Between podcast. In her previous roles as a clinician and Senior Trial Manager for Janssen Pharmaceuticals, Dr. Sims-Silbermann has remained an inquisitive observer and skilled facilitator for clinical studies in Europe, with a keen understanding of regulatory requirements and patient centricity.

Other Episodes

Episode 36

December 05, 2023 • 00:51:43

Episode 36: Zak Kohane, Department of Biomedical Informatics at Harvard Medical School

"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware...

Episode 38

February 22, 2024 • 00:38:27

Episode 38: Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School

"Artificial Intelligence is a tool that really levels up and creates almost like an equity for everybody to participate and, when used effectively, to...

Episode 63

October 28, 2025 • 01:01:16

Video Episode 63 - Bruce Leuchter, MD, President and CEO of Neurvati Neurosciences

What if the future of biotech is actually late-stage execution? Welcome to our first video episode of the Biorasi Few & Far Between podcast...